Westchester Capital Management (New York)’s Ibere Pharmaceuticals IBER Stock Holding History

Westchester Capital Management (New York)’s Portfolio IBER Stock Details IBER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-243,944	Closed	-$2.46M	–	485
2022 Q4	$2.46M	Buy	+243,944	New	+$2.44M	0.07%	269

Westchester Capital Management (New York)'s IBER Position: Q1 2023 in Review

Westchester Capital Management (New York) sold out of Ibere Pharmaceuticals (IBER) in Q1 2023, closing a stake of 243,944 shares — an estimated $2.46M sold.

Westchester Capital Management (New York) first reported a position in IBER in Q4 2022 and held it in 1 quarter. The position peaked at $2.46M in Q4 2022. 0 funds tracked by Wall St. Rank hold IBER as of Q1 2023.

Westchester Capital Management (New York) reported no remaining Ibere Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Westchester Capital Management (New York) sold 243,944 Ibere Pharmaceuticals shares in Q1 2023, an estimated $2.46M.
Westchester Capital Management (New York) first reported a position in Ibere Pharmaceuticals in Q4 2022 and held it in 1 quarter.
Westchester Capital Management (New York)'s Ibere Pharmaceuticals position peaked at $2.46M in Q4 2022.
0 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q1 2023.

Based on Westchester Capital Management (New York)'s 13F filing for Q1 2023, filed 15 May 2023.